CN102885801B - Application of Chinese medicinal monomer compound extracted from dragon's blood - Google Patents

Abstract

The invention relates to an application of a traditional Chinese medicine monomer compound, in particular to an application of a traditional Chinese medicine monomer compound extracted from Dracaena japonicus, belonging to the fields of biology and pharmacology, and is characterized in that: the traditional Chinese medicine extracted from Dracaena japonicus Application of monomeric compounds in the preparation of drugs for the prevention and treatment of scars; the traditional Chinese medicine monomeric compound extracted from Dracaena japonicus is dragon blood element B, and the chemical name of dragon blood element B is 4'-hydroxyl-2,4 , 6-trimethoxydihydrochalcone; the application of the dragon blood B in the preparation of medicines for preventing and treating scars. It provides the application of the traditional Chinese medicine monomer compound dragon blood in the field of scar prevention and treatment.

Description

Application of traditional Chinese medicine monomer compound extracted from dragon's blood

technical field

The invention relates to an application of a traditional Chinese medicine monomer compound, in particular to an application of a traditional Chinese medicine monomer compound extracted from Dracaena japonicus, belonging to the fields of biology and pharmacology.

Background technique

Scar is a natural product of human wound repair, and most tissue damage is repaired through scar formation in wound repair. Any type of biological, chemical or physical damage induces a cascade of humoral-cellular responses in the body, leading to a fibroproliferative inflammatory reaction process with fibrin as the main role, after which due to the imbalance of collagen synthesis and degradation metabolism , eventually leading to a large accumulation of collagen and scar formation.

According to statistics, millions of patients suffer from burns, scalds, trauma and other skin injuries every year, or secondary hypertrophic scars after surgery. There are about 4 million new scar cases in developed countries every year, and the annual cost of scar treatment in the United States alone is as high as 4 billion US dollars. For the research, prevention and treatment of scars, the whole world has invested huge manpower and financial resources.

Modern medicine has conducted in-depth research on the causes of scar formation, but due to the unclear mechanism of scar formation and poor healing effect, there is still no effective method to control scar formation so far. In traditional Chinese medicine, dracaena (Dracaena cochinchinensis (Lour.) S.C.Ghen.), a resinous medicinal material extracted from lipid-containing wood) has the functions of promoting blood circulation and removing blood stasis, relieving pain, relieving sores, and relieving sores. It is known as the "holy medicine for blood circulation" and is used for bruises, blood stasis and pain, stagnation of Qi and blood in women, traumatic blood, and abscesses that persist for a long time. A large number of studies have shown that the chemical composition of domestic dragon's blood is significantly similar to that of imported dragon's blood. Loureirin B (Loureirin B) is extracted from dragon's blood. Dragon's blood B is the main chemical component of dragon's blood. The chemical name is 4'-hydroxy-2,4,6-trimethoxydihydrochalle Ketone (C18H20O5), molecular weight 316.3484, chemical structural formula:

Dragon's blood B has a wide range of biological activities, including: promoting blood circulation and dispelling fatigue, reducing swelling and pain, astringent and hemostasis, adjusting the body's metabolism, and improving the body's immune function.

However, there are no related reports and written records about the application of Dracaena dracaena and its extract in the prevention and treatment of scars.

Contents of the invention

The purpose of the present invention is to provide an application of a traditional Chinese medicine monomer compound for preventing and treating scars, specifically the Chinese medicine monomer compound dragon blood element B (that is, 4'-hydroxyl-2,4,6-trimethoxydihydrochale Ketone) in the field of prevention and treatment of scars.

The technical scheme of the present invention is: the application of the monomeric compound of traditional Chinese medicine extracted from the dragon's blood, and the characteristic is: the application of the monomeric compound of the traditional Chinese medicine extracted from the dragon's blood in the preparation of the medicine for preventing and treating scar.

The traditional Chinese medicine monomer compound extracted from Dragon's Blood is Dragon Blood B, and the chemical name of Dragon Blood B is 4'-hydroxyl-2,4,6-trimethoxydihydrochalcone.

The application of the dragon blood B in the preparation of medicines for preventing and treating scars.

The dragon blood B can be used alone or mixed with other pharmaceutical carriers, and formulated into clinically used injections, sprays, aerosols, ointments, creams, coatings, patches or ointments.

Features of the present invention:

1. For the first time, the Chinese medicine dragon’s blood extract is used for post-traumatic prevention and inhibition of scar formation. At present, there are no domestic and foreign patents and marketed products for the preparation and clinical application of this drug. Therefore, if this product is launched, it will become a clinical trauma. The new bright spot of repair research can greatly improve the wound repair effect and quality of life of clinical patients.

2. The active drug used in the experiment of the present invention, the extract of dragon's blood, dragon's blood, has the function of locally degrading the extracellular matrix. After local administration, it can obviously reduce the formation of post-traumatic scars.

3. The active drug used in the experiment of the present invention is the monomeric compound of the extract of the traditional Chinese medicine dragon’s blood. The molecular formula is clear and can be artificially synthesized, and the drug structure is single. After local administration, the dose of the drug entering the blood circulation system through blood vessels can be reduced , clear effect, less side effects.

4. The dragon's blood extract Dracaena B disclosed in the present invention can be prepared into different administration forms, and can be used in the later stages of wound repair such as burns, scalds, abrasions, and stab wounds.

The essence of the present invention will be described below in conjunction with specific embodiments. It should be understood that these examples demonstrate the use of the monomeric compound of traditional Chinese medicine extracted from Dracaena japonicus according to the present invention, and are not intended to limit the scope of the present invention. The test methods for which specific conditions are not indicated in the following examples are usually in accordance with conventional conditions, or in accordance with the conditions suggested by the manufacturer.

Detailed ways

Example

Extraction of dragon blood B:

Take dragon's blood, pulverize, extract with chloroform several times, filter, combine the filtrates, recover chloroform to obtain chloroform extract, go through silica gel column chromatography, and elute with petroleum ether (60-90°C) ethyl acetate mixed solvent. Fractions containing dragon blood B were collected, combined, and subjected to silica gel column chromatography, and eluted with a mixed solvent of petroleum ether (60-90° C.) and ethyl acetate to obtain crude crystals. The crude crystals were repeatedly subjected to silica gel H column chromatography (pressurized) and eluted with a mixed solvent of chloroform-methanol to obtain dragon blood B crystals. Recrystallized from a mixed solvent of petroleum ether (60-90°C) and chloroform to obtain colorless needle-like crystals. The referenced literature (Liu Buming, et al. Research on the Chemical Reference Substance of Dragon Blood B, Guangxi Science Journal, 2006, 3(2): 133-134.) belongs to the well-known technology in the art, and will not be described in more detail here. Or buy directly from the market: You can get it from Shanghai Jingrong Biotechnology Co., Ltd., batch number: 111558-200405, and the company address is: Dongchang Road, Metro Line 2, Century Avenue, Lujiazui, Pudong, Shanghai.

1. Nude mouse scar transplantation experiment was carried out on the above-mentioned dragon blood B

1.1 Establishment of human skin scar tissue transplantation model in nude mice

Normal human skin scar samples were obtained from surgical resection of discarded scars (informed consent of patients had been obtained), 20 nude mice, 6-7 weeks old, weighing 25-30g, were raised at room temperature, male or female. 1.0 mL of 1% pentobarbital sodium was injected intraperitoneally. After the anesthesia took effect, a scalpel was used to create a full-thickness skin defect wound on the back with a size of 2 cm × 2 cm. After compression and hemostasis, the human scar specimen was transplanted on the back wound, covered with Vaseline gauze, and packed and bandaged fixed. After 14 days, the dressing was opened and the scar survival was observed.

1.2 Treatment of scars

Three weeks after skin transplantation, scar transplantation survived and was divided into groups for treatment, grouping situation: a. blank control group injected with normal saline; b. low-dose dragon blood group; c. medium-dose dragon blood group; d. dragon blood In group B, the high-dose group injected 0.5ml of drug at multiple points in the scar area every day. Among them, the effective concentrations of drugs in the low-dose dragon blood group, c. medium-dose group and d. high-dose group are 100ug/ml, 200ug/ml, and 500ug/ml respectively.

1.3 Observation indicators

After 30 days of treatment, the scar tissue samples of the dragon blood B treatment group were much smaller than those of the normal saline group, and the effect was concentration-dependent. Among them, the scar tissue in the high-dose dragon blood B treatment group was only 1/4 of the transplanted tissue, but there was no change in the saline injection group.

2. Rabbit ear scarring experiment

20 Japanese big-eared white rabbits, selected 4 sites on the ventral side of the rabbit ears, made 160 full-thickness skin and soft tissue defects with a diameter of 1 cm directly reaching the surface of the cartilage, and randomly divided them into groups after compression to stop bleeding. a. The blank control group was smeared with normal saline; b. The low-dose dragon blood B group; c. The middle dose dragon blood B group; d. The high-dose dragon blood B group. , 40 wounds in each group, the wounds were exposed, the drug was applied once every other day according to the group, and the granulation and plasma shell on the cartilage were removed once 7 days after injury. Observe the natural wound healing and scar hyperplasia for 3 consecutive months after operation

Observation indicators:

Changes in appearance of wound healing area and scar thickness

After the punching plate was positioned, the normal skin thickness of the rabbit ear in the center of the punching hole was measured with a vernier caliper, and the wound healing process and the color, texture, hyperplasia and degeneration of the scar growth were observed for 3 consecutive months from the second day after the wound was created, and then The scar thickness was measured at 15d, 30d, and 60d to evaluate whether there was scar growth. If the healing tissue was 1mm higher than the original surface, it was considered that there was scar growth, and d represented the number of days.

Table 1. Scar growth in each group

3. Balb/C mouse wound healing experiment

Twenty Balb/C male mice, 8 weeks old, (20±1.5g) were randomly divided into 4 groups. Hair removal on the back, and a 0.5cm×1cm full-thickness wound on the next day. Grouping situation: a. The blank control group was smeared with normal saline; b. The low-dose dragon blood B group; c. The middle dose dragon blood B group; d. The high dose dragon blood B group. Healing condition.

Observation indicators:

Changes in the appearance of the wound healing area

After 28 days, the area of the incision healing area of the mice treated with dragon blood B was significantly smaller than that of the blank control group in a concentration-dependent manner.

Changes in Collagen Deposition in the Wound Healing Area

After 28 days, the skin tissues in the healing area of the mice were excised, and fixed in 4% paraformaldehyde solution to prepare paraffin sections by conventional methods. H&E and collagen trichrome staining were performed to observe the collagen distribution around the healed incision and its tissue.

The results showed that the arrangement of collagen in the wound margin dermis of the dragon blood group B group was significantly more orderly than that of the control group.

Experimental results

In summary, dragon blood B has good preventive and therapeutic effects on scar formation.

The dragon blood B can be used alone or mixed with other pharmaceutical carriers, and formulated into clinically used injections, sprays, aerosols, ointments, creams, coatings, patches or ointments. The preparation methods of these dosage forms all adopt well-known or commonly used methods in the field of medicine, and are not described here one by one.

Claims (1)

1. The application of the traditional Chinese medicine monomer compound extracted from Dragon's Blood, characterized in that: the application of Dragon's Blood B extracted from Dragon's Blood as the only active ingredient in the preparation of medicine for treating scars; The traditional Chinese medicine monomer compound extracted from the root is dragon blood element B, and the chemical name of dragon blood element B is 4'-hydroxyl-2,4,6-trimethoxydihydrochalcone; Used alone or mixed with other pharmaceutical carriers, it is formulated into clinically used injections, sprays, aerosols, creams, coatings, patches or ointments.